Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: A case report

被引：6

作者：

Riera, Jordi ^{[1
,2
,3
]}

Domenech, Laura ^{[4
]}

Garcia, Sonia ^{[4
]}

Pau, Alba ^{[4
]}

Sosa, Manuel ^{[1
,2
]}

Domenech, Josep ^{[1
,2
]}

Palmada, Clara ^{[1
,2
]}

Torrella, Pau ^{[1
,2
]}

Sanchez, Ariadna ^{[1
]}

Lamora, Anna ^{[1
]}

Gallart, Elisabet ^{[1
,2
]}

Giron, Pilar ^{[1
,2
]}

Nuvials, Xavier ^{[1
,2
]}

Ferrer, Ricard ^{[1
,2
]}

机构：

[1] Vall dHebron Univ Hosp, Crit Care Dept, Barcelona, Spain

[2] Vall dHebron Res Inst, Organ Dysfunct & Resuscitat SODIR Res Grp, Sepsis, Barcelona, Spain

[3] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain

[4] Vall DHebron Univ Hosp, Pharm Dept, Barcelona, Spain

来源：

PERFUSION-UK | 2023年 / 38卷 / 1_SUPPL期

关键词：

ECMO; extracorporeal membrane oxygenation; pharmacokinetics; cefiderocol; microbial drug resistance;

D O I：

10.1177/02676591231160462

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with extracorporeal membrane oxygenation (ECMO) support do frequently receive broad-spectrum antibiotics, due to the high frequency of infection by multidrug resistant microorganisms. The extracorporeal circuit can alter the pharmacokinetics (PK) of administered drugs, and in the case of antibiotics this may lead to treatment failure. Cefiderocol is a new cephalosporin that exhibits excellent in vitro activity against many multidrug-resistant (MDR) microorganisms, but there is no published data about the modifications of its PK in patients with ECMO support. Herein we report the results of a pharmacokinetic investigation of cefiderocol in a critically ill patient receiving extracorporeal respiratory support.

引用

页码：40 / 43

页数：4

共 7 条

[1]

[Anonymous], FETROJA PRODUCT INFO

[2] Optimising drug dosing in patients receiving extracorporeal membrane oxygenation [J].

Cheng, Vesa ;

Abdul-Aziz, Mohd-Hafiz ;

Roberts, Jason A. ;

Shekar, Kiran .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S629-S641

[3]

Katsube T, 2021, J ANTIMICROB CHEMOTH, V76, P2902, DOI 10.1093/jac/dkab280

[4] Nosocomial infections during extracorporeal membrane oxygenation [J].

Martinez-Martinez, Maria ;

Nuvials, Francesc Xavier ;

Riera, Jordi .

CURRENT OPINION IN CRITICAL CARE, 2022, 28 (05) :480-485

[5] Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria [J].

Ong'uti, Sharon ;

Czech, Mary ;

Robilotti, Elizabeth ;

Holubar, Marisa .

CLINICAL INFECTIOUS DISEASES, 2022, 74 (07) :1303-1312

[6] Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects [J].

Saisho, Yutaka ;

Katsube, Takayuki ;

White, Scott ;

Fukase, Hiroyuki ;

Shimada, Jingoro .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (03)

[7] Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation [J].

Shekel, Kiran ;

Abdul-Aziz, Mohd H. ;

Cheng, Vesa ;

Burrows, Fay ;

Buscher, Hergen ;

Cho, Young-Jae ;

Corley, Amanda ;

Diehl, Arne ;

Gilder, Eileen ;

Jakob, Stephan M. ;

Kim, Hyung-Sook ;

Levkovich, Bianca J. ;

Lim, Sung Yoon ;

McGuinness, Shay ;

Parke, Rachael ;

Pellegrino, Vincent ;

Que, Yok-Ai ;

Reynolds, Claire ;

Rudham, Sam ;

Wallis, Steven C. ;

Welch, Susan A. ;

Zacharias, David ;

Fraser, John F. ;

Roberts, Jason A. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (06) :704-720

← 1 →